Local lymph node assay - validation, conduct and use in practice.
The validation of alternative methods is a relatively new activity in toxicology. The local lymph node assay (LLNA), a novel method for the identification of chemicals that have the potential to cause skin sensitization, was the first test to pass through the formal regulatory validation process established in the USA under the auspices of ICCVAM, the Interagency Coordinating Committee on the Validation of Alternative Methods. ICCVAM approved the LLNA as an alternative to guinea pig tests for the identification of skin sensitisation hazards. In this report, we explore the nine recommendations made by ICCVAM and discuss their interpretation in relation to the new OECD Guideline 429, which describes the LLNA. In particular, the value and limitations of the use of statistical evaluation of data and of the inclusion of routine positive controls is examined. It is concluded that the OECD Guideline as currently written embodies the necessary flexibility to permit conduct of the LLNA in a manner necessary to meet the varying needs of regulatory agencies and toxicologists around the world.
Basketter
D A
DA
SEAC, Unilever Colworth House, Sharnbrook, Beds MK44 1LQ, UK. david.basketter@unilever.com
Evans
P
P
Fielder
R J
RJ
Gerberick
G F
GF
Dearman
R J
RJ
Kimber
I
I
D000818:Animals; D003877:Dermatitis, Contact / Q000473:pathology*; D004353:Drug Evaluation, Preclinical; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology*; D051379:Mice; D008815:Mice, Inbred Strains; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012871:Skin Diseases / Q000139:chemically induced*; D013045:Species Specificity
D019275:Radiopharmaceuticals